The Melanoma Letter Spring 2010, Vol. 28, No. 1

In this issue of The Melanoma Letter, Bradley Bloom and Dr. David Polsky identify another high-risk gene called MDM2, which when mutated, and in the presence of estrogen, may increase a woman’s propensity for developing melanoma, especially at younger ages. If their findings are substantiated, it may help explain why younger women have higher melanoma incidence than younger men.

Based on the articles in this issue of The Melanoma Letter, it is compelling to contemplate just when clinical practice will evolve from the current phenotype-based screening and disease-based therapy to molecular/genetic-based targeted screening and therapy.